Recursion Pharmaceuticals Inc Clas (RXRX)
SG&A Expenses
$41.53M
Quarterly · Period ending: · USD
RXRX SG&A Expenses
Latest reported$41.53Mperiod ending
Latest reported$41.53Mperiod ending
RXRX Quarterly SG&A Expenses ($5.56M → $41.53M)
Quarterly SG&A Expenses
High-resolution chart · PNG
RXRX sg&a expenses history
Quarterly · USD. Dates are reporting period ends; fiscal years can differ from calendar years.
| Period ending | SG&A Expenses (USD) |
|---|---|
| 41,533,000 | |
| 34,591,000 | |
| 33,657,000 | |
| 41,628,000 | |
| 46,653,000 | |
| 54,650,000 | |
| 77,186,000 | |
| 37,757,000 | |
| 31,833,000 | |
| 31,408,000 | |
| 30,458,000 | |
| 29,199,000 | |
| 28,290,000 | |
| 22,874,000 | |
| 19,838,000 | |
| 19,488,000 | |
| 21,199,000 | |
| 21,074,000 | |
| 19,201,000 | |
| 15,690,000 | |
| 13,854,000 | |
| 8,937,000 | |
| 7,574,000 | |
| 6,964,000 | |
| 5,159,000 | |
| 5,561,000 |